Skip to content

App-based Intervention for Treating Insomnia Among Patients With Epilepsy

App-based Intervention for Treating Insomnia Among Patients With Epilepsy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03683381
Enrollment
320
Registered
2018-09-25
Start date
2018-09-26
Completion date
2019-10-01
Last updated
2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Insomnia

Brief summary

Sleep can affect frequency and occurrence of interictal spikes and occurrence, timing, and threshold of seizure. Epilepsy can worsen sleep architecture and severity of sleep disorders. Thus, a vicious cycle is set. Certain epilepsy syndromes are so intertwined with sleep that they are considered sleep-related epilepsies. Poor sleep in epilepsy is multifactorial and is worsened by poorly controlled seizures. App-delivered intervention has shown promise as a method to overcome health issues; however, the long-term effectiveness has not been proven in epileptic patients with chronic insomnia.

Interventions

BEHAVIORALSleep Health

Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep

OTHERPatient education

Participants in the Patient education group will receive weekly information on insomnia symptoms

Sponsors

Qazvin University Of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Are at least 18 years of age * diagnosis of epilepsy according to the International League Against Epilepsy criteria * Self-report moderate or severe insomnia as indicated by a score of 15 or higher on the Insomnia Severity Index * Can speak, understand, and write in Persian * No surgery planned in the next 6 months * Have access to an Android smartphone or a desktop computer with Internet access * absence of major cognitive impairment or active psychiatric disorders

Exclusion criteria

* presence of a rapidly progressing neurological or medical disorder * a diagnosis of mental retardation * use of drugs or alcohol * Untreated sleep apnea * Current pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Insomnia symptomschanges in ISI baseline , 1 month, 3 months and 6 months follow-upIsomnia symptom severity will be assessed using the Insomnia Severity Index
sleep hygiene behaviorchanges in sleep hygiene behavior baseline , 1 month, 3 months and 6 months follow-upSleep hygiene behaviour will use three items to measure how many days the participants had good sleep hygiene. behaviour.
objective sleep measurechanges in objective sleep baseline , 1 month and 6 months follow-upSleep data is measured by Actigraphy (total minutes asleep, sleep effectiveness, sleep latency, awakenings). A wrist actigraph will be worn by the patients for 7 consecutive days.

Secondary

MeasureTime frameDescription
Psychological predictors of sleep hygiene behavior (attitude, habit, self monitoring, self control, perceived behavior controlchanges from baseline , changes from baseline , 1 month and 6 Months follow-uppsychological predictors of sleep hygiene behavior will be assessed using a using a self-reported measure. All items are rated on a Likert-type scale, ranging from 1 to 5.
Health related Quality of lifechanges from baseline, changes from baseline , 1 month and 6 Months follow-upquality of Life in Epilepsy (QOLIE-31) will be used to assess quality of life
Anxiety and Depressionchanges from baseline , changes from baseline , 1 month and 6 Months follow-upZigmond and Snaith developed the 14-item HADS to measure the anxiety (7 items) and depression (7 items) of patients with both somatic and mental problems. The response descriptors of all items are Yes, definitely (score 3); Yes, sometimes (score 2); No, not much (score 1); No, not at all (score 0); except for items 7 and 10, which are scored reversely. A higher score represents higher levels of anxiety and depression: a domain score of 11 or greater indicates anxiety or depression; 8-10 indicates borderline case; 7 or lower indicates no signs of anxiety or depression. The two-factor framework of the HADS has been supported in epileptic patients.

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026